stockportfolio.pro
Praxis Precision Medicines, Inc. (PRAX)
Healthcare · Biotechnology · NasdaqGS
Praxis Precision Medicines, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $2.45M | $8.55M | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-35.51M | $-61.82M | $-167.06M | $-214.03M | $-123.28M | $-182.82M | $-303.27M |
| Net margin | — | — | — | — | -5037.9% | -2137.5% | — |
Source: Praxis Precision Medicines, Inc. SEC filings (10-K).
Explore 7 years of Praxis Precision Medicines, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PRAX in your portfolio →
Praxis Precision Medicines, Inc. financial history by metric
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Praxis Precision Medicines, Inc. — frequently asked questions
What is Praxis Precision Medicines, Inc.'s revenue?
Praxis Precision Medicines, Inc. (PRAX) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Praxis Precision Medicines, Inc. profitable?
No — PRAX reported a net loss of $-303.27M in fiscal 2025.
What is PRAX's P/E ratio?
Praxis Precision Medicines, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Praxis Precision Medicines, Inc. have?
As of fiscal year 2025, PRAX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Praxis Precision Medicines, Inc.'s market cap?
Praxis Precision Medicines, Inc. (PRAX) has a market capitalization of about $6.81B, based on the latest data in our nightly-refreshed cache.
When does Praxis Precision Medicines, Inc.'s fiscal year end?
PRAX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Praxis Precision Medicines, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.